Source:http://linkedlifedata.com/resource/pubmed/id/12782020
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2003-6-3
|
| pubmed:abstractText |
TNF-alpha is a proinflammatory cytokine, abundantly expressed after myocardial infarction. It has been suggested that it exhibits myocardial suppressive and cytotoxic effects. AG-556 is a tyrosine kinase inhibitor synthesized based on its ability to reduce TNF-alpha production and cell toxicity, and to improve experimental models mediated by TNF-alpha (i.e., peritontitis and experimental autoimmune encephalomyelitis). Daily, for 7 days, rats were injected ip with either AG-556 dissolved in DMSO or with the control vehicle. Infarct size was determined in the hearts as well as in fibrous scar formation. Cardiac TNF-alpha expression was evaluated by ELISA and immunohistochemistry. Functional hemodynamic parameters were evaluated employing echocardiography prior to sacrifice. AG-556 treatment reduced MI size at 7 days with a parallel effect on fibrous tissue formation. TNF-alpha production by splenocytes was reduced upon AG-556 treatment, whereas no differences were evident between the groups with regard to myocardial cytokine expression. AG-556 attenuated the decrease in fractional shortening at the expense of preserving end systolic diameter. AG-556 has proven beneficial in reducing myocardial infarct size and attenuated consequent hemodynamic deterioration in the rat model. If reconfirmed, AG-556 may be of potential clinical use in post-MI patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AG 556,
http://linkedlifedata.com/resource/pubmed/chemical/Peroxidase,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrphostins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0014-4800
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
74
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
314-8
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:12782020-Animals,
pubmed-meshheading:12782020-Disease Models, Animal,
pubmed-meshheading:12782020-Echocardiography,
pubmed-meshheading:12782020-Heart,
pubmed-meshheading:12782020-Heart Ventricles,
pubmed-meshheading:12782020-Immunohistochemistry,
pubmed-meshheading:12782020-Injections, Intraperitoneal,
pubmed-meshheading:12782020-Male,
pubmed-meshheading:12782020-Myocardial Infarction,
pubmed-meshheading:12782020-Myocardium,
pubmed-meshheading:12782020-Peroxidase,
pubmed-meshheading:12782020-Protein-Tyrosine Kinases,
pubmed-meshheading:12782020-Rats,
pubmed-meshheading:12782020-Rats, Wistar,
pubmed-meshheading:12782020-Spleen,
pubmed-meshheading:12782020-Tumor Necrosis Factor-alpha,
pubmed-meshheading:12782020-Tyrphostins,
pubmed-meshheading:12782020-Ventricular Remodeling
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat.
|
| pubmed:affiliation |
Department of Cardiology and the Cardiovascular Research Laboratory, Tel-Aviv Medical Center, Tel-Aviv, Israel. jacobg@post.tau.ac.il
|
| pubmed:publicationType |
Journal Article
|